Document is current
Any future updates will be listed below
-
Authors
Pereira, Manuel P. https://orcid.org/0009-0008-0162-0742
Salameh, Pascale https://orcid.org/0000-0002-4780-0772
Tsianakas, Athanasios https://orcid.org/0000-0003-1563-7402
Szymczak, Hermann https://orcid.org/0000-0002-5550-3110
Apfelbacher, Christian https://orcid.org/0000-0003-3805-8219
Ständer, Sonja https://orcid.org/0000-0003-3612-7786
Zeidler, Claudia https://orcid.org/0000-0002-9485-8627
-
Funding
Funding for this research was provided by:
Novartis Pharma (unrestricted grant)
- License Information
-
More Information
Article History
Received: 7 May 2026
Accepted: 22 June 2026
First Online: 7 July 2026
Declarations
:
: Manuel P. Pereira has received research funding from Almirall, Clinuvel, Leo Pharma, and Pfizer; is an investigator for Amgen, Allakos, ARS Pharmaceuticals, Celldex Therapeutics, Escient, Incyte, InflaRx, Mitsubishi, and Sanofi; has received consulting fees from Almirall, Amgen, Galderma, Incyte, Novartis, and Sanofi; and has received speaker honoraria and/or travel fees from AbbVie, Amgen, Beiersdorf, Celltrion, CSL Behring, Doctorflix, Eli Lilly, Falk Foundation, FomF GmbH, GA2LEN, Galderma, Novartis, P.G. Unna Academy, Sanofi, StreamedUP, TouchMDT, and Zai Lab. Pascale Salameh declares no conflict of interest. Athanasios Tsianakas declares no conflict of interest. Hermann Szymczak declares no conflict of interest. Christian Apfelbacher has received institutional funding from Bionorica SE and consultancy fees from Bionorica SE, Dr Wolff Group, Incyte, LEO Pharma, Pfizer, WECARE, IVDK, and GFCNI. He is co-chair of the Harmonising Outcome Measures for Eczema (HOME) and Hand Eczema Core Outcome Set (HECOS) initiatives. Sonja Ständer is an Editorial Board member of Dermatology and Therapy . Sonja Ständer was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Sonja Ständer received grants from Almirall, Beiersdorf, Galderma, Sanofi Genzyme, and Trevi Therapeutics; consulting fees from AbbVie, Amgen, Bellus Health, Bristol-Meyers Squibb, Clexio, Galderma, Innocare Pharma, Klirna Biotech, Omnicuris Healthcare Private Ltd., Pfizer, P. G. Unna Academy, Sanofi, Vifor, and Zai Laboratory; honoraria from Beiersdorf, CRM GmbH, FomF GmbH, Galderma, L’Oréal, Novartis, Pfizer, P. G. Unna Akademie, Sanofi, Streamed-Up!, TouchIME, UCB, Vifor, and WebMD; support for attending meetings from AbbVie, Attovia Therapeutics, Galderma, Lilly, Pfizer, Sanofi, Trevi Therapeutics, and Vifor; and participation on boards for AbbVie, Almirall, Amgen, Celldex, Focus-Insight Healthtech, Galderma, Grünenthal, Lilly, Regeneron, Sanofi, and Vifor. Claudia Zeidler has received consulting fees from Galderma and speaker honoraria/travel fees from AbbVie, Almirall, Celldex, Dermasence, Leo, Novartis, Sanofi, and Unna Akademie.
